Whalesbook
WHO Approval: A Global Stamp of Quality
The World Health Organization's prequalification for Anuh Pharma's Amodiaquine Hydrochloride USP marks a significant regulatory achievement. This approval from the WHO Prequalification of Medicines Programme designates the active pharmaceutical ingredient (API) as eligible for use in international markets, especially within WHO-procured and donor-funded global health initiatives targeting malaria. The product meets strict United States Pharmacopeia (USP) standards and confirms Anuh Pharma's manufacturing capabilities align with global quality benchmarks.
Key Role in Malaria Fight
Amodiaquine Hydrochloride is an essential medicine, crucial for malaria combination therapies. The WHO prequalification positions Anuh Pharma as an eligible supplier for procurement programs aimed at combating malaria, a disease affecting millions worldwide, particularly in sub-Saharan Africa and tropical areas. This regulatory success strengthens the company's standing in the fight against this persistent illness.
Anuh Pharma: A Long-Standing Manufacturer
Anuh Pharma Limited, a bulk drug manufacturer and part of the SK Group, has a 60-year history in India's pharmaceutical sector. The company is a major producer of macrolides and anti-TB drugs, with a strong presence in anti-bacterials and anti-malarials. Its focus on APIs for essential medicines has helped build solid relationships with global public health procurement entities.
Stock Reaction to Approval
Anuh Pharma shares rose 6.6% on the BSE, reaching an intraday high of ₹85 per share. By midday, the stock was trading up 6.15% at ₹84.6. This performance significantly outpaced the broader market, with the BSE Sensex down 0.74% at 76,700.92. The surge reflects strong investor confidence following the crucial WHO approval.